Fredrik Kryh Öberg

Dr. Fredrik Kryh Öberg

Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Maaloev, Denmark
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2011 in Journal of Biological Chemistry
Verified
Journal Article
Open access
FÖFredrik Kryh Öberg
Fredrik Kryh Öberg
JSJennie Sjöhamn
Jennie Sjöhamn
GFGerhard Fischer
Gerhard Fischer
AMAndreas Moberg
Andreas Moberg
APAnders Pedersen
Anders Pedersen
KHKristina Hedfalk
Kristina Hedfalk
Human aquaporin10 (hAQP10) is a transmembrane facilitator of both water and glycerol transport in the small intestine. This aquaglyceroporin is located in the apical membrane of enterocytes and is believed to contribute to the passage of water and glycerol through these intestinal absorptive cells. Here we overproduced hAQP10 in the yeast Pichia pastoris and observed that the protein is glycosylated at Asn-133 in the extracellular loop C. This finding confirms one of three predicted glycosylation sites for hAQP10, and its glycosylation is unique for the human aquaporins overproduced in this host. Nonglycosylated protein was isolated using both glycan affinity chromatography and through mutating asparagine 133 to a glutamine. All three forms of hAQP10 where found to facilitate the transport of water, glycerol, erythritol, and xylitol, and glycosylation had little effect on functionality. In contrast, glycosylated hAQP10 showed increased thermostability of 3-6 °C compared with the nonglycosylated protein, suggesting a stabilizing effect of the N-linked glycan. Because only one third of hAQP10 was glycosylated yet the thermostability titration was mono-modal, we suggest that the presence of at least one glycosylated protein within each tetramer is sufficient to convey an enhanced structural stability to the remaining hAQP10 protomers of the tetramer.

1 August 2021 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
RBRafael Bayarri-Olmos
Rafael Bayarri-Olmos
MIManja Idorn
Manja Idorn
ARAnne Rosbjerg
Anne Rosbjerg
LPLaura Pérez-Alós
Laura Pérez-Alós
CHCecilie Bo Hansen
Cecilie Bo Hansen
PGPeter Garred
Peter Garred
Tools to monitor SARS-CoV-2 transmission and immune responses are needed. We present a neutralization ELISA to determine the levels of Ab-mediated virus neutralization and a preclinical model of focused immunization strategy. The ELISA is strongly correlated with the elaborate plaque reduction neutralization test (ρ = 0.9231, p < 0.0001). The neutralization potency of convalescent sera strongly correlates to IgG titers against SARS-CoV-2 receptor-binding domain (RBD) and spike (ρ = 0.8291 and 0.8297, respectively; p < 0.0001) and to a lesser extent with the IgG titers against protein N (ρ = 0.6471, p < 0.0001). The preclinical vaccine NMRI mice models using RBD and full-length spike Ag as immunogens show a profound Ab neutralization capacity (IC50 = 1.9 × 104 to 2.6 × 104 and 3.9 × 103 to 5.2 × 103, respectively). Using a panel of novel high-affinity murine mAbs, we also show that a majority of the RBD-raised mAbs have inhibitory properties, whereas only a few of the spike-raised mAbs do. The ELISA-based viral neutralization test offers a time- and cost-effective alternative to the plaque reduction neutralization test. The immunization results indicate that vaccine strategies focused only on the RBD region may have advantages compared with the full spike. Key Points We have developed a quick and sensitive ELISA to monitor SARS-CoV-2 -neutralizing Ab response. Mice immunized with RBD have a higher Ab neutralizing response compared to spike-immunized mice.

17 August 2021 in Cells
Verified
Journal Article
Open access
PDF file
CCChivasso Clara
Chivasso Clara
VNVeronika Nesverova
Veronika Nesverova
MJMichael Järvå
Michael Järvå
ABAnne Blanchard
Anne Blanchard
KRKristie L Rose
Kristie L Rose
CDChristine Delporte
Christine Delporte
Saliva secretion requires effective translocation of aquaporin 5 (AQP5) water channel to the salivary glands (SGs) acinar apical membrane. Patients with Sjögren’s syndrome (SS) display abnormal AQP5 localization within acinar cells from SGs that correlate with sicca manifestation and glands hypofunction. Several proteins such as Prolactin-inducible protein (PIP) may regulate AQP5 trafficking as observed in lacrimal glands from mice. However, the role of the AQP5-PIP complex remains poorly understood. In the present study, we show that PIP interacts with AQP5 in vitro and in mice as well as in human SGs and that PIP misexpression correlates with an altered AQP5 distribution at the acinar apical membrane in PIP knockout mice and SS hMSG. Furthermore, our data show that the protein-protein interaction involves the AQP5 C-terminus and the N-terminal of PIP (one molecule of PIP per AQP5 tetramer). In conclusion, our findings highlight for the first time the role of PIP as a protein controlling AQP5 localization in human salivary glands but extend beyond due to the PIP-AQP5 interaction described in lung and breast cancers.

4 January 2021 in Research Square
Verified
Preprint
Open access
PDF file
RBRafael Bayarri-Olmos
Rafael Bayarri-Olmos
MIManja Idorn
Manja Idorn
ARAnne Rosbjerg
Anne Rosbjerg
LPLaura Pérez-Alós
Laura Pérez-Alós
CHCecilie Hansen
Cecilie Hansen
PGPeter Garred
Peter Garred
Effective tools to monitor SARS-CoV-2 transmission and humoral immune responses are highly needed. Protective humoral immunity involves neutralizing antibodies and will be a hallmark for the evaluation of a vaccine response efficacy. Here we present a sensitive, fast and simple neutralization ELISA method to determine the levels of antibody-mediated virus neutralization. We can show that it is strongly correlated with the more elaborate plaque reduction neutralization test (PRNT) (ρ = 0.9231, p < 0.0001). Furthermore, we present pre-clinical vaccine models using recombinant receptor binding domain (RBD) and full-length spike antigen as immunogens showing a profound antibody neutralization capacity that exceeds the highest neutralization titers from convalescent individuals. Using a panel of novel high-affinity murine monoclonal antibodies (mAbs) we also show that majority of the RBD-raised mAbs have inhibitory properties while only a few of the spike-raised mAbs do. In conclusion, the ELISA-based viral neutralization test offers a time- and cost-effective alternative to the PRNT. The immunization results indicate that vaccine strategies focused only on the RBD region may have major advantages over those based on the full spike sequence.